This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stavenhagen, J. B. Articles by Koenig, S. Search for Related Content PubMed PubMed Citation Articles by Stavenhagen, J. B. Articles by Koenig, S.

Fc Optimization of Therapeutic Antibodies Enhances Their Ability to Kill Tumor Cells In vitro and Controls Tumor Expansion In vivo via Low-Affinity Activating Fc Receptors

MacroGenics, Inc., Rockville, Maryland

Requests for reprints: Jeffrey B. Stavenhagen, MacroGenics, Inc., 1500 East Gude Drive, Rockville, MD 20850. Phone: 301-354-2604; Fax: 301-251-5321; E-mail: stavenhagenj{at}macrogenics.com.

Monoclonal antibodies (mAb) are widely used in the treatment of non-Hodgkin's lymphoma and autoimmune diseases. Although the mechanism of action in vivo is not always known, the therapeutic activity of several approved mAbs depends on the binding of the Fc regions to low-affinity Fc receptors (FcR) expressed on effector cells. We did functional genetic screens to identify IgG1 Fc domains with improved binding to the low-affinity activating Fc receptor CD16A (FcRIIIA) and reduced binding to the low-affinity inhibitory Fc receptor, CD32B (FcRIIB). Identification of new amino acid residues important for FcR binding guided the construction of an Fc domain that showed a dramatically enhanced CD16A binding and greater than a 100-fold improvement in antibody-dependent cell-mediated cytotoxicity. In a xenograft murine model of B-cell malignancy, the greatest enhancement of an Fc-optimized anti-human B-cell mAb was accounted for by improved binding to FcRIV, a unique mouse activating FcR that is expressed by monocytes and macrophages but not natural killer (NK) cells, consistent with experimental and clinical data suggesting that mononuclear phagocytes, effector cells expressing both activating and inhibitory FcR, are critical mediators of B-cell depletion in vivo. By using mice transgenic for human CD16A, enhanced survival was observed due to expression of CD16A-158^phe on monocytes and macrophages as well as on NK cells in these mice. The design of new generations of improved antibodies for immunotherapy should aim at Fc optimization to increase the engagement of activating FcR present on the surface of tumor-infiltrating effector cell populations. [Cancer Res 2007;67(18):8882–90]

This article has been cited by other articles:

				J. O. Richards, S. Karki, G. A. Lazar, H. Chen, W. Dang, and J. R. Desjarlais Optimization of antibody binding to Fc{gamma}RIIa enhances macrophage phagocytosis of tumor cells Mol. Cancer Ther., August 1, 2008; 7(8): 2517 - 2527. [Abstract] [Full Text] [PDF]

				P. Zhou, R. L. Comenzo, A. B. Olshen, E. Bonvini, S. Koenig, P. G. Maslak, M. Fleisher, J. Hoffman, S. Jhanwar, J. W. Young, et al. CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy Blood, April 1, 2008; 111(7): 3403 - 3406. [Abstract] [Full Text] [PDF]